Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00467077 · ClinicalTrials.gov registry record · Phase 2
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
A Phase 2 study, sponsored by California Cancer Consortium.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00467077 is a Phase 2 study that was terminated before completion, run by California Cancer Consortium. The registered enrollment target is 21 participants.
The verdict
NCT00467077, a Phase 2 study, was terminated before completion, sponsored by California Cancer Consortium.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
RATIONALE: Gefitinib may stop the growth of kidney cancer by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. PEG-interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of kidney cancer. Giving gefitinib together with PEG-interferon alfa-2b may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gefitinib together with PEG-interferon alfa-2b works in treating patients with unresectable or metastatic kidney cancer.
Interventions
- DRUG gefitinib
- BIOLOGICAL PEG-interferon alfa-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2004-09 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00467077
The ClinicalTrials.gov registry entry for NCT00467077 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is California Cancer Consortium, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gefitinib is the first listed.
NCT00467077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00467077 about?
NCT00467077 is a clinical study titled "Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer". RATIONALE: Gefitinib may stop the growth of kidney cancer by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. PEG-interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of kidney cancer. Giving gefitinib together with PEG-inter...
What is the current status of trial NCT00467077?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2004-09. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00467077?
The interventions under investigation include: gefitinib (DRUG), PEG-interferon alfa-2b (BIOLOGICAL).
Who is sponsoring clinical trial NCT00467077?
This trial is sponsored by California Cancer Consortium, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.